Kums Juliane, Nelke Johannes, Rüth Benedikt, Schäfer Viktoria, Siegmund Daniela, Wajant Harald
a Division of Molecular Internal Medicine, Department of Internal Medicine II , University Hospital Würzburg , Würzburg , Germany.
MAbs. 2017 Apr;9(3):506-520. doi: 10.1080/19420862.2016.1274844. Epub 2017 Jan 17.
Cell surface antigen-specific antibodies are of substantial diagnostic and therapeutic importance. The binding properties of such antibodies are usually evaluated by cell-free assays, in particular surface plasmon resonance (SPR) analysis, or flow cytometry. SPR analyses allow the detailed quantitative and dynamic evaluation of the binding properties of antibodies, but need purified, typically recombinantly produced antigens. It can, however, be difficult to produce the required antigen. Furthermore, cellular factors influencing the antigen-antibody interaction are not considered by this method. Flow cytometry-based analyses do not have these limitations, but require elaborated calibration controls for absolute quantification of bound molecules. To overcome the limitations of SRP and flow cytometry in the characterization of cell surface antigen-specific antibodies, we developed Fn14-specific antibody 18D1 as an example of an antibody fusion protein format that includes the luciferase of Gaussia princeps (GpL), which enables very simple and highly sensitive cellular binding studies. We found that GpL-tagging of the C-terminus of the antibody light chain does not affect the interaction of 18D1-IgG1 with its antigen and Fc-gamma receptors (FcγRs). In accordance with this, the GpL-18D1-IgG1 antibody fusion protein showed basically the same FcγR-dependent agonistic properties as the parental 18D1 antibody. Similar results were obtained with isotype switch variants of 18D1 and antibodies specific for CD95, LTβR and CD40. In sum, we demonstrate that antibody GpL fusion proteins are easily manageable and versatile tools for the characterization of cell surface antigen-antibody interactions that have the potential to considerably extend the instrumentarium for the evaluation of antibodies.
细胞表面抗原特异性抗体具有重要的诊断和治疗意义。此类抗体的结合特性通常通过无细胞检测进行评估,特别是表面等离子体共振(SPR)分析或流式细胞术。SPR分析能够对抗体的结合特性进行详细的定量和动态评估,但需要纯化的、通常是重组产生的抗原。然而,生产所需的抗原可能会很困难。此外,该方法未考虑影响抗原 - 抗体相互作用的细胞因子。基于流式细胞术的分析不存在这些局限性,但需要精心设计的校准对照来绝对定量结合的分子。为了克服SPR和流式细胞术在表征细胞表面抗原特异性抗体方面的局限性,我们开发了Fn14特异性抗体18D1作为抗体融合蛋白形式的一个例子,该形式包含高斯海萤(GpL)的荧光素酶,这使得非常简单且高度灵敏的细胞结合研究成为可能。我们发现,抗体轻链C末端的GpL标记不会影响18D1 - IgG1与其抗原和Fc - γ受体(FcγRs)的相互作用。据此,GpL - 18D1 - IgG1抗体融合蛋白表现出与亲本18D1抗体基本相同的FcγR依赖性激动特性。用18D1的同种型转换变体以及针对CD95、LTβR和CD40的特异性抗体也获得了类似结果。总之,我们证明抗体GpL融合蛋白是用于表征细胞表面抗原 - 抗体相互作用的易于操作且通用的工具,有可能极大地扩展评估抗体的手段。